Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Parallel, Blinded, Randomized Comparison of the Safety and Efficacy of Balloon Angioplasty Plus Intraluminal SBCV To Balloon Angioplasty Alone for Treatment of Stenosis or Occlusion Within the Femoropopliteal Artery

Trial Profile

A Multicenter, Parallel, Blinded, Randomized Comparison of the Safety and Efficacy of Balloon Angioplasty Plus Intraluminal SBCV To Balloon Angioplasty Alone for Treatment of Stenosis or Occlusion Within the Femoropopliteal Artery

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Feb 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SB 030 (Primary)
  • Indications Peripheral arterial disorders; Vascular disorders
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Acronyms SHIELD
  • Most Recent Events

    • 02 Apr 2018 According to a Symic Bio media release, data from extension phase (12-month follow-up) demonstrates statistically significant reduction in index limb re-intervention of treatment group compared with the control group.
    • 02 Apr 2018 Results of extension phase (12-month follow-up), presented in a Symic Bio media release.
    • 01 Nov 2017 Results presented in a Symic Bio Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top